Investors Plump For Xbrane With EU Ranibizumab Launch Plans Near
Ximluci Biosimilar Launch Eyed Early In 2023, With Stada To Commercialize
Sweden’s Xbrane BioPharma has followed through on plans to tap the equity markets for cash to fuel the planned launch of its Ximluci (ranibizumab) biosimilar version of Lucentis in Europe.
